Gravibinan injection was primarily used for the treatment of habitual abortion.
Gravibinan Injection: A Detailed Look
Here's a breakdown of what Gravibinan injection was used for, based on available information:
- Primary Use: The medication, developed by Schering and marketed as Gravibinon in Europe, was intended for the treatment of habitual abortion. This means it was prescribed for women who had a history of repeated miscarriages.
Additional Insights
-
Historical Context: Gravibinon was marketed in Europe by the late 1960s, reflecting the medical understanding and treatment options available during that era.
-
EV/OHPC Connection: While Gravibinon was primarily for habitual abortion, it's also important to note that the combination of estradiol valerate and hydroxyprogesterone caproate (EV/OHPC) was first studied as a combined injectable contraceptive. It was initially evaluated in 1963 by Siegel and colleagues. Although EV/OHPC is related, it's crucial to distinguish that the marketed purpose of Gravibinon was focused on preventing habitual abortion.
Key Takeaway
The core function of Gravibinon injection was to address the issue of repeated pregnancy loss, offering a treatment option for women struggling with habitual abortion.
